Brad Shumel (B Shumel)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 15

Top Topics

Peritoneal Dialysis

Clinical Evaluation

Loop Mediated Isothermal Amplification

Top Venues

Dermatology and therapy

Pediatric dermatology

The British journal of dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

Mike Bastian, Nick Freemantle, Ana Beatris Rossi, Brad Shumel, Gaelle Bego Le Bagousse, Zhixiao Wang, Yingxin Xu, Patricia Guyot
Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'. Dermatology and therapy 14 (3) (2024)
Mike Bastian, Nick Freemantle, Ana Beatris Rossi, Brad Shumel, Gaelle Bego Le Bagousse, Zhixiao Wang, Yingxin Xu, Patricia Guyot
Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'. Dermatology and therapy (2024)
Mike Bastian, Nick Freemantle, Ana Beatris Rossi, Brad Shumel, Gaelle Bego Le Bagousse, Zhixiao Wang, Yingxin Xu, Patricia Guyot
Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'. Dermatology and therapy 14 (3) (2024)
Mike Bastian, Nick Freemantle, Ana Beatris Rossi, Brad Shumel, Gaelle Bego Le Bagousse, Zhixiao Wang, Yingxin Xu, Patricia Guyot
Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'. Dermatology and therapy 14 (3) (2024)
Mike Bastian, Nick Freemantle, Ana Beatris Rossi, Brad Shumel, Gaelle Bego Le Bagousse, Zhixiao Wang, Yingxin Xu, Patricia Guyot
Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'. Dermatology and therapy (2024)
Elaine C Siegfried, Lara Wine Lee, Jonathan M Spergel, Randy Prescilla, Sumeet Uppal, Anna Coleman, Ashish Bansal, Sonya L Cyr, Brad Shumel
A case series of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitis. Pediatric dermatology (2024)
Mike Bastian, Nick Freemantle, Ana Beatris Rossi, Brad Shumel, Gaelle Bego Le Bagousse, Zhixiao Wang, Yingxin Xu, Patricia Guyot
Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'. Dermatology and therapy 14 (3) (2024)
Elaine C Siegfried, Lara Wine Lee, Jonathan M Spergel, Randy Prescilla, Sumeet Uppal, Anna Coleman, Ashish Bansal, Sonya L Cyr, Brad Shumel
A case series of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitis. Pediatric dermatology 41 (2) (2024)
Mike Bastian, Nick Freemantle, Ana Beatris Rossi, Brad Shumel, Gaelle Bego Le Bagousse, Zhixiao Wang, Yingxin Xu, Patricia Guyot
Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab Versus Dupilumab in Moderate-to-Severe Atopic Dermatitis'. Dermatology and therapy 14 (3) (2024)
Elaine C Siegfried, Lara Wine Lee, Jonathan M Spergel, Randy Prescilla, Sumeet Uppal, Anna Coleman, Ashish Bansal, Sonya L Cyr, Brad Shumel
A case series of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitis. Pediatric dermatology 41 (2) (2024)
Andrew Blauvelt, Marjolein de Bruin-Weller, Eric L Simpson, Zhen Chen, Annie Zhang, Brad Shumel
Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks. Dermatology and therapy (2021)
Gil Yosipovitch, Marjolein de Bruin-Weller, April W Armstrong, Jashin J Wu, Pedro Herranz Pinto, Diamant Thaҫi, Dimittri Delevry, Gaëlle Bégo-Le Bagousse, Raymond Zhang, Brad Shumel, Ana Beatris Rossi, Jingdong Chao
Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis. Dermatology and therapy 11 (6) (2021)
April Armstrong, Andrew Blauvelt, Eric L Simpson, Catherine H Smith, Pedro Herranz, Yoko Kataoka, Seong Jun Seo, Silvia M Ferrucci, Jingdong Chao, Zhen Chen, Ana B Rossi, Brad Shumel, Paul Tomondy
Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment. Dermatology and therapy 12 (1) (2021)
A S Paller, J K L Tan, J Bagel, Ana Beatris Rossi, Brad Shumel, H Zhang, A Abramova
IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis. The British journal of dermatology (2021)
Marius Ardeleanu, Brad Shumel, Ana Beatris Rossi, N M H Graham
Response to R. Waldman et al.: 'Does IL-4 inhibition play a role in dupilumab-associated conjunctivitis?' The British journal of dermatology 182 (5) (2020)